Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $9.66 Consensus Target Price from Analysts

Revance Therapeutics, Inc. (NASDAQ:RVNC) has earned a consensus recommendation of “Hold” from the nine brokerages that are presently covering the stock, MarketBeat reports. Eight equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $9.66.

Several equities research analysts have issued reports on the stock. StockNews.com began coverage on shares of Revance Therapeutics in a research report on Sunday, November 10th. They set a “hold” rating for the company. Guggenheim restated a “neutral” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. William Blair reiterated a “market perform” rating on shares of Revance Therapeutics in a report on Monday, August 12th. HC Wainwright reiterated a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a report on Friday, November 8th. Finally, Stifel Nicolaus decreased their price objective on Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating for the company in a report on Friday, August 9th.

Revance Therapeutics Trading Down 3.2 %

RVNC stock opened at $4.17 on Tuesday. The stock has a 50-day moving average price of $5.41 and a two-hundred day moving average price of $4.44. The stock has a market cap of $437.43 million, a PE ratio of -2.16 and a beta of 0.95. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. On average, analysts forecast that Revance Therapeutics will post -1.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RVNC. BNP Paribas Financial Markets raised its position in Revance Therapeutics by 342.1% in the 1st quarter. BNP Paribas Financial Markets now owns 211,695 shares of the biopharmaceutical company’s stock worth $1,042,000 after purchasing an additional 163,809 shares during the period. Swiss National Bank raised its position in Revance Therapeutics by 18.2% in the 1st quarter. Swiss National Bank now owns 194,650 shares of the biopharmaceutical company’s stock worth $958,000 after purchasing an additional 30,000 shares during the period. NorthRock Partners LLC purchased a new position in Revance Therapeutics in the 1st quarter worth $151,000. Inspire Investing LLC raised its position in Revance Therapeutics by 68.1% in the 1st quarter. Inspire Investing LLC now owns 73,160 shares of the biopharmaceutical company’s stock worth $360,000 after purchasing an additional 29,645 shares during the period. Finally, Blair William & Co. IL raised its position in Revance Therapeutics by 3.6% in the 1st quarter. Blair William & Co. IL now owns 329,267 shares of the biopharmaceutical company’s stock worth $1,620,000 after purchasing an additional 11,318 shares during the period. 97.70% of the stock is owned by institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.